Back to top
Top
U.S. flag

An official website of the United States government

Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer

eCQM Compare View

Compare Versions of: "Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer"

The Compare function compares two years of the measure specifications found in the header of the measure's HTML. It does not include a comparison of any information in the body of the HTML, e.g., population criteria, Clinical Quality Language, or value sets.

Strikethrough text highlighted in red indicates information changed from the previous version. Text highlighted in green indicates information updated in the new eCQM version.

Compare 2023 version to

Table Options
Measure Information 2023 Performance Period
Title Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer
CMS eCQM ID CMS646v3
CBE ID* Not Applicable
MIPS Quality ID 481
Measure Steward Oregon Urology
Description

Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging

Measure Scoring Proportion
Measure Type Process
Stratification *See CMS646v3.html
Risk Adjustment *See CMS646v3.html
Rationale *See CMS646v3.html
Clinical Recommendation Statement *See CMS646v3.html
Improvement Notation

A higher score is the preferred result and indicates better quality

Definition *See CMS646v3.html
Guidance

Ta bladder cancer must be high grade Ta only and is supported by the 2016 AUA guidelines and 2018 NCCN guidelines.

The BCG dose can be full or partial and can be from any lot or manufacturer.

This eCQM is a patient-based measure.

Telehealth encounters are not eligible for this measure...

Show more >
Initial Population

All patients initially diagnosed with T1, Tis or high grade Ta non-muscle invasive bladder cancer and a qualified encounter in the measurement period

Denominator

Equals Initial Population

Denominator Exclusions

Immunosuppressed patients, includes HIV and immunocompromised state.

Immunosuppressive drug therapy.

Active Tuberculosis.

Mixed histology urothelial cell carcinoma including micropapillary, plasmacytoid, sarcomatoid, adenocarcinoma and squamous disease.

Patients who undergo cystectomy,...

Show more >
Numerator

Intravesical Bacillus-Calmette Guerin (BCG) instillation for initial dose or series

BCG is initiated within 6 months of the bladder cancer staging and during the measurement period

Numerator Exclusions

Not Applicable

Denominator Exceptions

Unavailability of BCG

Telehealth Eligible No
Next Version No Version Available
Previous Version No Version Available
Last Updated: May 01, 2025